Home › Funds › NEXTBio Capital Management LP › ACET
NEXTBio Capital Management LP position in ACET
ADICET BIO INC · Health Care
NEXTBio Capital Management LP reported holding 157,827 shares of ACET (ADICET BIO INC) in its Q2 2026 13F filing — a position valued at US$1.4M, representing 0.63% of its reported portfolio and ranking #22 among its reported holdings. NEXTBio Capital Management LP has disclosed ACET holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's ACET position evolved
NEXTBio Capital Management LP first disclosed a stake in ACET in Q4 2025 at 157,827 shares (US$1.3M). The position peaked in Q2 2026 at 157,827 shares, worth US$1.4M. Across 3 filings, NEXTBio Capital Management LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 157,827 shares valued at US$1.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 157.83K | $1.33M | New |
| Q1 2026 | 157.83K | $1.07M | Hold |
| Q2 2026 | 157.83K | $1.36M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACET and 13F data
ACET (ADICET BIO INC) is a Health Care company. 27 other funds we track also report a position in ACET — the largest reported positions include Stonepine Capital Management, LLC (US$2.1M), Carlyle Group Inc. (US$1.6M), REGENERON PHARMACEUTICALS, INC. (US$523K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACET
- Stonepine Capital Management, LLC 245.52K sh · $2.12M · Q2 2026
- Carlyle Group Inc. 184.29K sh · $1.59M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 60.51K sh · $522.82K · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held ACET?
NEXTBio Capital Management LP has disclosed ACET holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in ACET?
As of Q2 2026, NEXTBio Capital Management LP holds 157.83K shares of ACET (ADICET BIO INC), valued at $1.36M, representing 0.63% of its reported portfolio and ranking #22.
Has NEXTBio Capital Management LP been buying or selling ACET?
In the latest 13F filing (Q2 2026), NEXTBio Capital Management LP held unchanged its position in ACET. The position peaked in Q2 2026 at 157.83K shares.
Which other funds hold ACET?
Other major institutional holders of ACET include Stonepine Capital Management, LLC, Carlyle Group Inc., REGENERON PHARMACEUTICALS, INC., among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.